120 related articles for article (PubMed ID: 24007820)
1. Positron emission tomography imaging of oestrogen receptor-expression in endometrial stromal sarcoma supports oestrogen receptor-targeted therapy: case report and review of the literature.
van Kruchten M; Hospers GA; Glaudemans AW; Hollema H; Arts HJ; Reyners AK
Eur J Cancer; 2013 Dec; 49(18):3850-5. PubMed ID: 24007820
[TBL] [Abstract][Full Text] [Related]
2. Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.
van Kruchten M; de Vries EG; Glaudemans AW; van Lanschot MC; van Faassen M; Kema IP; Brown M; Schröder CP; de Vries EF; Hospers GA
Cancer Discov; 2015 Jan; 5(1):72-81. PubMed ID: 25380844
[TBL] [Abstract][Full Text] [Related]
3. ¹⁸F-Fluorodeoxyglucose uptake and clinicopathological features of recurrent or metastatic endometrial stromal sarcoma.
Inoue K; Tsubamoto H; Kawata S; Hao H; Ikeda Y; Oku N; Hirota S
J Obstet Gynaecol Res; 2014 Feb; 40(2):576-82. PubMed ID: 24118160
[TBL] [Abstract][Full Text] [Related]
4. Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo?
Yang Z; Sun Y; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y
Clin Breast Cancer; 2013 Oct; 13(5):359-63. PubMed ID: 23787040
[TBL] [Abstract][Full Text] [Related]
5. Aromatase inhibitor therapy for endometrial stromal sarcoma - two-centre experience.
Serkies K; Abacjew-Chmyłko A; Wieczorek-Rutkowska M; Pęksa R
Ginekol Pol; 2018; 89(11):607-610. PubMed ID: 30508212
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader.
Heidari P; Deng F; Esfahani SA; Leece AK; Shoup TM; Vasdev N; Mahmood U
Clin Cancer Res; 2015 Mar; 21(6):1340-7. PubMed ID: 25609068
[TBL] [Abstract][Full Text] [Related]
7. Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas.
Reich O; Regauer S; Urdl W; Lahousen M; Winter R
Br J Cancer; 2000 Mar; 82(5):1030-4. PubMed ID: 10737385
[TBL] [Abstract][Full Text] [Related]
8.
Wang Y; Ayres KL; Goldman DA; Dickler MN; Bardia A; Mayer IA; Winer E; Fredrickson J; Arteaga CL; Baselga J; Manning HC; Mahmood U; Ulaner GA
Clin Cancer Res; 2017 Jun; 23(12):3053-3060. PubMed ID: 28011460
[No Abstract] [Full Text] [Related]
9. Functional images reflect aggressiveness of endometrial carcinoma: estrogen receptor expression combined with 18F-FDG PET.
Tsujikawa T; Yoshida Y; Kudo T; Kiyono Y; Kurokawa T; Kobayashi M; Tsuchida T; Fujibayashi Y; Kotsuji F; Okazawa H
J Nucl Med; 2009 Oct; 50(10):1598-604. PubMed ID: 19759112
[TBL] [Abstract][Full Text] [Related]
10. The Application of 18 F-FES PET in Clinical Cancer Care : A Systematic Review.
Huang YT; Chen TW; Chen LY; Huang YY; Lu YS
Clin Nucl Med; 2023 Sep; 48(9):785-795. PubMed ID: 37482660
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of steroid receptor positivity and adjuvant progestogen use in endometrial stromal sarcoma.
Cade TJ; Quinn MA; Rome RM; Polyakov A
Aust N Z J Obstet Gynaecol; 2014 Oct; 54(5):453-6. PubMed ID: 25287561
[TBL] [Abstract][Full Text] [Related]
12. Functional oestrogen receptor α imaging in endometrial carcinoma using 16α-[¹⁸F]fluoro-17β-oestradiol PET.
Tsujikawa T; Yoshida Y; Kiyono Y; Kurokawa T; Kudo T; Fujibayashi Y; Kotsuji F; Okazawa H
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):37-45. PubMed ID: 20717823
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the novel estrogen receptor PET tracer 4-fluoro-11β-methoxy-16α-[(18)F]fluoroestradiol (4FMFES) by PET imaging in a breast cancer murine model.
Paquette M; Phoenix S; Ouellet R; Langlois R; van Lier JE; Turcotte EE; Bénard F; Lecomte R
Mol Imaging Biol; 2013 Oct; 15(5):625-32. PubMed ID: 23619898
[TBL] [Abstract][Full Text] [Related]
14. Utility of
Lin FI; Gonzalez EM; Kummar S; Do K; Shih J; Adler S; Kurdziel KA; Ton A; Turkbey B; Jacobs PM; Bhattacharyya S; Chen AP; Collins JM; Doroshow JH; Choyke PL; Lindenberg ML
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):500-508. PubMed ID: 27872957
[TBL] [Abstract][Full Text] [Related]
15. Investigation of hormone receptor expression and its prognostic value in endometrial stromal sarcoma.
Park JY; Baek MH; Park Y; Kim YT; Nam JH
Virchows Arch; 2018 Jul; 473(1):61-69. PubMed ID: 29869299
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography of tumour [(18)F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy.
van Kruchten M; Glaudemans AWJM; de Vries EFJ; Schröder CP; de Vries EGE; Hospers GAP
Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1674-1681. PubMed ID: 26091705
[TBL] [Abstract][Full Text] [Related]
17. PET imaging of oestrogen receptors in patients with breast cancer.
van Kruchten M; de Vries EGE; Brown M; de Vries EFJ; Glaudemans AWJM; Dierckx RAJO; Schröder CP; Hospers GAP
Lancet Oncol; 2013 Oct; 14(11):e465-e475. PubMed ID: 24079874
[TBL] [Abstract][Full Text] [Related]
18. Estrogen replacement therapy and tamoxifen are contraindicated in patients with endometrial stromal sarcoma.
Reich O; Regauer S
Gynecol Oncol; 2006 Aug; 102(2):413-4; author reply 414. PubMed ID: 16712906
[No Abstract] [Full Text] [Related]
19. Long-term survival of patients given hormonal therapy for metastatic endometrial stromal sarcoma.
Spano JP; Soria JC; Kambouchner M; Piperno-Neuman S; Morin F; Morere JF; Martin A; Breau JL
Med Oncol; 2003; 20(1):87-93. PubMed ID: 12665689
[TBL] [Abstract][Full Text] [Related]
20. Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy.
Cheng X; Yang G; Schmeler KM; Coleman RL; Tu X; Liu J; Kavanagh JJ
Gynecol Oncol; 2011 May; 121(2):323-7. PubMed ID: 21277011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
